NasdaqGS - Nasdaq Real Time Price • USD
Nanobiotix S.A. (NBTX)
As of 9:34 AM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO | 677.62k | -- | 1973 |
| Mr. Bart Van Rhijn | CFO & Member of Executive Board | 601.13k | -- | 1973 |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board | 330.47k | -- | 1974 |
| Mr. Earl J. Bergey Ph.d. | Co-Founder | -- | -- | 1955 |
| Mr. Alain Dostie | Chief Operating Officer | -- | -- | -- |
| Mr. Craig West CFA | Senior Vice President of Investor Relations | -- | -- | -- |
| Mr. Brandon Owens | VP of Strategic Marketing & Corporate Communication | -- | -- | -- |
| Mr. Patrick Tricoli M.B.A., Pharm.D. | Global Head of Business Development | -- | -- | -- |
| Ms. Margaret Galluzzi | VP & Global Head of Clinical Operations | -- | -- | -- |
| Mr. Ventzislav Vassilev M.D. | VP & Global Head of Safety Vigilance | -- | -- | -- |
Nanobiotix S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 101
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Corporate Governance
Nanobiotix S.A.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 17, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 10, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 06, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 13, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 31, 20246-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available
Related Tickers
LENZ LENZ Therapeutics, Inc.
16.85
-3.66%
IGMS IGM Biosciences, Inc.
7.35
-0.81%
ENTA Enanta Pharmaceuticals, Inc.
13.06
-1.29%
REPL Replimune Group, Inc.
6.71
-3.73%
IMCR Immunocore Holdings plc
55.94
+2.18%
MGTX MeiraGTx Holdings plc
5.09
+1.60%
STTK Shattuck Labs, Inc.
9.97
-1.58%
PHVS Pharvaris N.V.
18.14
-1.52%
AGIO Agios Pharmaceuticals, Inc.
30.10
+2.28%
INZY Inozyme Pharma, Inc.
4.5050
-1.64%